Patients with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis,

 

Abstract

Patients with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are at increased risk for arterial and venous thrombosis/thromboembolism. In particular, the risk of splanchnic venous thrombosis, such as portal vein thrombosis or Budd-Chiari syndrome, is significantly higher in patients with MPN than in the normal population. At the same time, MPN patients are at increased risk for severe bleeding. Therefore, the treatment of patients with MPN must be based on their suspected probability of thrombosis/thromboembolism and bleeding. For this purpose, patient and MPN-specific risk factors are used. Patients at expected high risk of thrombosis should receive adequate primary or secondary thromboprophylaxis in addition to cytoreductive therapy. This may consist of antiplatelet agents and/or anticoagulant agents and must be balanced with the individual bleeding risk. The goal is to increase the quality of life and life span of patients with MPNs by preventing (re-)thrombosis and severe bleeding.

PMID: 32050290 [PubMed - in process]

12:38

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

12:38

In reply to this message

pubmed: caandvteortroorpul

Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation.

Related Articles

Prospective evaluation of drug-drug interactions in ambulatory cancer patients initiated on prophylactic anticoagulation.

J Oncol Pharm Pract. 2020 Feb 11;:1078155220901569

Authors: Ng HK, Rogala BG, Ades S, Schwartz JR, Ashikaga T, Vacek P, Holmes CE

PMID: 32046579 [PubMed - as supplied by publisher]

14:39

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

14:39

In reply to this message

pubmed: ctoall&ca or conall

Escalation and de-escalation in HER2 positive early breast cancer.

//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--tools.ovid.com-images-wklogo.jpg Related Articles

Escalation and de-escalation in HER2 positive early breast cancer.

Curr Opin Oncol. 2019 01;31(1):35-42

Authors: Dieci MV, Vernaci G, Guarneri V